Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Hayman

Showing results (251-260 of 446) with videos related to

Pageof 45
Sort By:
American Journal of Hematology|June 30, 2019
Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosisSurbhi Sidana, M Hasib Sidiqi, Angela Dispenzieri, et al.
Leukemia|November 28, 2019
Revisiting complete response in light chain amyloidosisSurbhi Sidana, Angela Dispenzieri, David L Murray, et al.
American Journal of Hematology|February 4, 2016
Clinical characteristics and outcomes in biclonal gammopathiesTrey C Mullikin, S Vincent Rajkumar, Angela Dispenzieri, et al.
American Journal of Hematology|November 23, 2013
Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapyTaxiarchis V Kourelis, Shaji K Kumar, Geetika Srivastava, et al.
Leukemia|November 12, 2021
Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosisAlissa Visram, Celine Vachon, Linda B Baughn, et al.
Leukemia & Lymphoma|May 26, 2020
Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practiceAmber B Koehler, Nelson Leung, Timothy G Call, et al.
American Journal of Hematology|July 6, 2019
Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosisAbdullah S Al Saleh, M Hasib Sidiqi, Surbhi Sidana, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 6, 2011
Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantationSandra M S Herrmann, Morie A Gertz, Mark D Stegall, et al.
Mayo Clinic Proceedings|October 3, 2007
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myelomaMartha Q Lacy, Morie A Gertz, Angela Dispenzieri, et al.
Leukemia|October 12, 2021
Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myelomaSaurabh Zanwar, Matthew Ho, Prashant Kapoor, et al.
Pageof 45

Showing results (251-260 of 446) with videos related to

Sort By:
Pageof 45
American Journal of Hematology|June 30, 2019
Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosisSurbhi Sidana, M Hasib Sidiqi, Angela Dispenzieri, et al.
Leukemia|November 28, 2019
Revisiting complete response in light chain amyloidosisSurbhi Sidana, Angela Dispenzieri, David L Murray, et al.
American Journal of Hematology|February 4, 2016
Clinical characteristics and outcomes in biclonal gammopathiesTrey C Mullikin, S Vincent Rajkumar, Angela Dispenzieri, et al.
American Journal of Hematology|November 23, 2013
Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapyTaxiarchis V Kourelis, Shaji K Kumar, Geetika Srivastava, et al.
Leukemia|November 12, 2021
Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosisAlissa Visram, Celine Vachon, Linda B Baughn, et al.
Leukemia & Lymphoma|May 26, 2020
Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practiceAmber B Koehler, Nelson Leung, Timothy G Call, et al.
American Journal of Hematology|July 6, 2019
Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosisAbdullah S Al Saleh, M Hasib Sidiqi, Surbhi Sidana, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 6, 2011
Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantationSandra M S Herrmann, Morie A Gertz, Mark D Stegall, et al.
Mayo Clinic Proceedings|October 3, 2007
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myelomaMartha Q Lacy, Morie A Gertz, Angela Dispenzieri, et al.
Leukemia|October 12, 2021
Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myelomaSaurabh Zanwar, Matthew Ho, Prashant Kapoor, et al.
Pageof 45